Bin Su, Cheng Yao, Qing-Xia Zhao, Wei-Ping Cai, Min Wang, Hong-Zhou Lu, Yuan-Yuan Chen, Li Liu, Hui Wang, Yun He, Yu-Huang Zheng, Ling-Hua Li, Jin-Feng Chen, Jian-Hua Yu, Biao Zhu, Min Zhao, Yong-Tao Sun, Wen-Hui Lun, Wei Xia, Li-Jun Sun, Li-Li Dai, Tai-Yi Jiang, Mei-Xia Wang, Qing-Shan Zheng, Hai-Yan Peng, Yao Wang, Rong-Jian Lu, Jian-Hua Hu, Hui Xing, Yi-Ming Shao, Dong Xie, Tong Zhang, Fu-Jie Zhang, Hao Wu
BACKGROUND: Albuvirtide is a once-weekly injectable human immunodeficiency virus (HIV)-1 fusion inhibitor. We present interim data for a phase 3 trial assessing the safety and efficacy of albuvirtide plus lopinavir-ritonavir in HIV-1-infected adults already treated with antiretroviral drugs. METHODS: We carried out a 48-week, randomized, controlled, open-label non-inferiority trial at 12 sites in China. Adults on the World Health Organization (WHO)-recommended first-line treatment for >6 months with a plasma viral load >1000 copies/mL were enrolled and randomly assigned (1:1) to receive albuvirtide (once weekly) plus ritonavir-boosted lopinavir (ABT group) or the WHO-recommended second-line treatment (NRTI group)...
November 25, 2020: Chinese Medical Journal